Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
111M
-
Number of holders
-
134
-
Total 13F shares, excl. options
-
73.9M
-
Shares change
-
+24.1M
-
Total reported value, excl. options
-
$262M
-
Value change
-
+$85.1M
-
Put/Call ratio
-
0.58
-
Number of buys
-
80
-
Number of sells
-
-46
-
Price
-
$3.54
Significant Holders of Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) as of Q1 2025
161 filings reported holding AMLX - Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share as of Q1 2025.
Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) has 134 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 73.9M shares
of 111M outstanding shares and own 66.69% of the company stock.
Largest 10 shareholders include PERCEPTIVE ADVISORS LLC (7.87M shares), TCG Crossover Management, LLC (5.94M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (5.7M shares), VANGUARD GROUP INC (4.12M shares), MILLENNIUM MANAGEMENT LLC (3.08M shares), Nantahala Capital Management, LLC (2.93M shares), CITADEL ADVISORS LLC (2.76M shares), Aberdeen Group plc (2.43M shares), Saturn V Capital Management LP (2.43M shares), and 683 Capital Management, LLC (2.41M shares).
This table shows the top 134 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.